Get the Stockscreener App
7.40
3.93%
0.28
Amicus Therapeutics Inc stock is traded at $7.40, with a volume of 4.67M.
It is up +3.93% in the last 24 hours and up +25.21% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$7.12
Open:
$7.2
24h Volume:
4.67M
Relative Volume:
0.99
Market Cap:
$2.28B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-21.76
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+9.47%
1M Performance:
+25.21%
6M Performance:
-24.26%
1Y Performance:
-35.37%
1-Day Range:
$7.15
$7.42
1-Week Range:
$6.61
$7.42
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
7.40 | 2.19B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
What analysts say about Amicus Therapeutics Inc. stock outlook2025 Buyback Activity & Risk Controlled Stock Alerts - Newser
Regression analysis insights on Amicus Therapeutics Inc. performanceWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
Can trapped investors hope for a rebound in Amicus Therapeutics Inc.Quarterly Profit Review & AI Powered Market Entry Ideas - Newser
Will earnings trigger a reversal in Amicus Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - Newser
Amicus Therapeutics Inc. Recovery Likely Here’s What Data ShowsPortfolio Update Report & Daily Technical Stock Forecast Reports - beatles.ru
What’s the recovery path for long term holders of Amicus Therapeutics Inc.2025 AllTime Highs & Technical Analysis for Trade Confirmation - Newser
Using economic indicators to assess Amicus Therapeutics Inc. potential2025 Technical Overview & Stock Portfolio Risk Management - Newser
Published on: 2025-08-14 05:57:55 - Newser
Connor Clark & Lunn Investment Management Ltd. Buys 483,698 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
What institutional flow reveals about Amicus Therapeutics Inc.2025 Earnings Impact & Expert Approved Momentum Trade Ideas - Newser
Heatmap Data Shows High Activity in Amicus Therapeutics Inc. Sector [Trade Analysis Summary]Weekly Market Pulse Updates - 선데이타임즈
Has Amicus Therapeutics Inc. formed a bullish divergenceFree Daily Smart Money Movement Monitor - Newser
Applying Wyckoff theory to Amicus Therapeutics Inc. stockTrade Alert System with Volume Analysis - Newser
Why is Amicus Therapeutics Inc. stock going downMassive Profit Potential Picks - mustnews.co.kr
Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% HigherShould You Buy? - MarketBeat
What candlestick patterns are forming on Amicus Therapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
How Efficient Is Amicus Therapeutics Inc. at Controlling Operating CostsFree ROI Boosting Trade Opportunity Calendar - Newser
Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wall Street Zen Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy - MarketBeat
Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? - Yahoo Finance
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Upgraded at Wall Street Zen - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat
Amicus Therapeutics Inc. Rebound Backed by Sentiment ShiftFundamental + Technical Hybrid Stock Tips Shared - metal.it
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... By GuruFocus - Investing.com Canada
What are the latest earnings results for Amicus Therapeutics Inc.Invest in stocks with strong fundamentals - Jammu Links News
Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful portfolio management tools - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News
What catalysts could drive Amicus Therapeutics Inc. stock higher in 2025Phenomenal trading returns - Jammu Links News
When is Amicus Therapeutics Inc. stock expected to show significant growthDiscover stocks with massive upside potential - Jammu Links News
What are the technical indicators suggesting about Amicus Therapeutics Inc.Get daily expert analysis on top stocks - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
What drives Amicus Therapeutics Inc. stock priceMaximize your portfolio’s growth with expert tips - Jammu Links News
How does Amicus Therapeutics Inc. compare to its industry peersExceptional market performance - Jammu Links News
Should I hold or sell Amicus Therapeutics Inc. stock in 2025Unlock exclusive stock market insights - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Is it the right time to buy Amicus Therapeutics Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Amicus Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mesirow Financial Investment Management Inc. Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Victory Capital Management Inc. Purchases 82,691 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics Reports Strong Growth Amid Strategic Advances - The Globe and Mail
Amicus Therapeutics' Q2 Performance: A Glimpse into Rare Disease Growth and Strategic Risks - AInvest
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):